SeaStar Medical, a medical technology company, has filed an amended annual report for the fiscal year ended December 31, 2023. The amendment, submitted on July 3, 2024, includes additional exhibits that were inadvertently omitted from the original filing with the Securities and Exchange Commission (SEC) on April 16, 2024, and the subsequent amendment on April 26, 2024. The exhibits added pertain to various agreements and warrants related to the company's financial and business dealings. No other changes have been made to the original report, and the amendment does not reflect any new information post the original filing date. The company's aggregate market value of common equity held by non-affiliates was reported at $23,606,503 as of July 3, 2024, with 3,221,104 shares of common stock outstanding as of July 5, 2024. SeaStar...Show More

SeaStar Medical, a medical technology company, has filed an amended annual report for the fiscal year ended December 31, 2023. The amendment, submitted on July 3, 2024, includes additional exhibits that were inadvertently omitted from the original filing with the Securities and Exchange Commission (SEC) on April 16, 2024, and the subsequent amendment on April 26, 2024. The exhibits added pertain to various agreements and warrants related to the company's financial and business dealings. No other changes have been made to the original report, and the amendment does not reflect any new information post the original filing date. The company's aggregate market value of common equity held by non-affiliates was reported at $23,606,503 as of July 3, 2024, with 3,221,104 shares of common stock outstanding as of July 5, 2024. SeaStar Medical's business development activities over the past year included a series of agreements and partnerships, such as a merger plan with LMF Acquisition Opportunities, Inc., and a license and distribution agreement with NuWellis, Inc. The company's future plans and strategic initiatives were not detailed in the amendment. SeaStar Medical is categorized as a non-accelerated filer, smaller reporting company, and emerging growth company, indicating its current stage of development.